These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 25586068)

  • 21. Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy.
    Usui C; Hatta K; Doi N; Kubo S; Kamigaichi R; Nakanishi A; Nakamura H; Hattori N; Arai H
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1704-8. PubMed ID: 21605615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychotic and depressive symptoms in Parkinson's disease. A study of the growth hormone response to apomorphine.
    Mellers JD; Quinn NP; Ron MA
    Br J Psychiatry; 1995 Oct; 167(4):522-6. PubMed ID: 8829723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychotic symptoms in Parkinson's disease. From description to etiology.
    Papapetropoulos S; Mash DC
    J Neurol; 2005 Jul; 252(7):753-64. PubMed ID: 15999234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?
    Zahodne LB; Fernandez HH
    CNS Spectr; 2008 Mar; 13(3 Suppl 4):26-33. PubMed ID: 18323764
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dopaminomimetic psychosis in Parkinson's disease: first symptom of early dementia?].
    Catalan-Alonso MJ; Del Val J
    Rev Neurol; 2001 Jun 1-15; 32(11):1085-7. PubMed ID: 11562835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopaminergic psychosis in advanced Parkinson's disease.
    Fischer P; Danielczyk W; Simanyi M; Streifler MB
    Adv Neurol; 1990; 53():391-7. PubMed ID: 2122647
    [No Abstract]   [Full Text] [Related]  

  • 27. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.
    Juncos JL; Roberts VJ; Evatt ML; Jewart RD; Wood CD; Potter LS; Jou HC; Yeung PP
    Mov Disord; 2004 Jan; 19(1):29-35. PubMed ID: 14743357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clozapine and olanzapine in the treatment of the psychotic disorders in Parkinson's disease].
    Chacón J
    Rev Neurol; 2004 Oct 1-15; 39(7):655-60. PubMed ID: 15490354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
    Lin JJ; Yueh KC; Lin SZ; Harn HJ; Liu JT
    J Neurol Sci; 2007 Jan; 252(2):130-4. PubMed ID: 17196621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parkinson's disease psychosis 2010: a review article.
    Friedman JH
    Parkinsonism Relat Disord; 2010 Nov; 16(9):553-60. PubMed ID: 20538500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hallucinations and psychosis in Parkinson's disease.
    Rabey JM
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S105-10. PubMed ID: 20123547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poor visual discrimination and visual hallucinations in Parkinson's disease.
    Diederich NJ; Goetz CG; Raman R; Pappert EJ; Leurgans S; Piery V
    Clin Neuropharmacol; 1998; 21(5):289-95. PubMed ID: 9789709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and evaluation of the Parkinson Psychosis Questionnaire A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease.
    Brandstaedter D; Spieker S; Ulm G; Siebert U; Eichhorn TE; Krieg JC; Oertel WH; Eggert K
    J Neurol; 2005 Sep; 252(9):1060-6. PubMed ID: 15789127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Compulsive behaviors in patients with Parkinson's disease.
    Kenangil G; Ozekmekçi S; Sohtaoglu M; Erginöz E
    Neurologist; 2010 May; 16(3):192-5. PubMed ID: 20445429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Levodopa dependency in Parkinson's disease: case report and review].
    Müller U; Reuter M; Hermann W; Gertz HJ
    Nervenarzt; 2002 Sep; 73(9):887-91. PubMed ID: 12215883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clozapine in the treatment of psychosis in Parkinson's disease.
    Friedman JH; Lannon MC
    Neurology; 1989 Sep; 39(9):1219-21. PubMed ID: 2771073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Features associated with the development of hallucinations in Parkinson's disease.
    Benbir G; Ozekmekçi S; Cinar M; Beskardes F; Apaydin H; Erginöz E
    Acta Neurol Scand; 2006 Oct; 114(4):239-43. PubMed ID: 16942542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychosis in Parkinson's disease.
    Wint DP; Okun MS; Fernandez HH
    J Geriatr Psychiatry Neurol; 2004 Sep; 17(3):127-36. PubMed ID: 15312276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined clozapine and electroconvulsive therapy for the treatment of drug-induced psychosis in Parkinson's disease.
    Factor SA; Molho ES; Brown DL
    J Neuropsychiatry Clin Neurosci; 1995; 7(3):304-7. PubMed ID: 7580188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between age and subtypes of psychotic symptoms in Parkinson's disease.
    Kiziltan G; Ozekmekçi S; Ertan S; Ertan T; Erginöz E
    J Neurol; 2007 Apr; 254(4):448-52. PubMed ID: 17401525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.